Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22368484 | 1.00 | KCNA5 (0.35) | KCNA5GLADHFRKMT2ACTSL | |
| SCHEMBL19990788 | 0.89 | KCNA5 (0.37) | KCNA5GLADHFRCTSLALDH1A1 | |
| SCHEMBL22368470 | 0.89 | KCNA5 (0.37) | KCNA5GLADHFRCTSLALDH1A1 | |
| SCHEMBL19990955 | 0.80 | KCNA5 (0.37) | KCNA5DHFRKMT2ACTSLCTSB | |
| SCHEMBL22368496 | 0.80 | KCNA5 (0.37) | KCNA5DHFRKMT2ACTSLCTSB | |
| SCHEMBL22368502 | 0.77 | KCNA5 (0.37) | KCNA5DHFRKMT2AALDH1A1 | |
| SCHEMBL20009179 | 0.77 | KCNA5 (0.37) | KCNA5DHFRKMT2AALDH1A1 | |
| SCHEMBL22368497 | 0.75 | ALOX15 (0.35) | KCNA5DHFR | |
| SCHEMBL19990666 | 0.75 | ALOX15 (0.35) | KCNA5DHFR | |
| SCHEMBL19990952 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3519419-B1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-10597396-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10065957-B2 | Beta-lactamase inhibitors | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177324-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | KCNA5 2796/4885GLA 4/4885DHFR 516/4885 |
| US-10597396-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | KCNA5 2796/4885GLA 4/4885DHFR 516/4885 |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | KCNA5 2796/4885GLA 4/4885DHFR 516/4885 |
| US-10065957-B2 | Beta-lactamase inhibitors | MGAM, LCT, GAA | KCNA5 2796/4885GLA 4/4885DHFR 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.